What's Going On With Merck Stock Wednesday? - Merck & Co (NYSE:MRK)

What's Going On With Merck Stock Wednesday? - Merck & Co (NYSE:MRK)

Biotechnology firm Infinimmune Inc. on Tuesday entered a collaboration with Merck & Co Inc. (NYSE:MRK) to develop antibody candidates using its human-first discovery platform. The agreement enables Merck to leverage Infinimmune's proprietary technologies to identify therapies targeting multiple undisclosed programs. Merck Secures Exclusive Development And Commercial Rights Under the terms, Merck will gain exclusive rights to develop and commerci…

Merck strikes deal with antibody discovery startup

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets.

Merck joins forces with small startup to find therapeutic antibodies

Merck is tasking a 10-person biotech to hunt for new human antibody candidates. The drug giant will ship up to $838 million to the startup, called Infinimmune, in exchange for antibody candidates that are directed ...